within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX52_Venetoclax;

model Venetoclax
  extends Pharmacolibrary.Drugs.ATC.L.L01XX52;

  annotation (Documentation(
info       = "<html><body><table><tr><td>name:</td><td>Venetoclax</td></tr><tr><td>ATC code:</td><td>L01XX52</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Venetoclax is a selective inhibitor of B-cell lymphoma-2 (BCL-2) protein, used primarily for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). It promotes apoptosis of cancer cells by inhibiting BCL-2, a protein that helps cancer cells survive. Venetoclax is an approved drug for hematological malignancies.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are based on adults with hematologic malignancies receiving single or multiple oral doses. The values mainly reflect patients with normal hepatic and renal function.</p><h4>References</h4><ol><li><p>DiNardo, CD, et al., &amp; Pollyea, DA (2018). Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. <i>The Lancet. Oncology</i> 19(2) 216–228. DOI:<a href=\"https://doi.org/10.1016/S1470-2045(18)30010-X\">10.1016/S1470-2045(18)30010-X</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29339097/\">https://pubmed.ncbi.nlm.nih.gov/29339097</a></p></li><li><p>Jones, AK, et al., &amp; Salem, AH (2016). Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin&#x27;s Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis. <i>The AAPS journal</i> 18(5) 1192–1202. DOI:<a href=\"https://doi.org/10.1208/s12248-016-9927-9\">10.1208/s12248-016-9927-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27233802/\">https://pubmed.ncbi.nlm.nih.gov/27233802</a></p></li><li><p>King, AC, et al., &amp; Tang, LA (2017). Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies. <i>The Annals of pharmacotherapy</i> 51(5) 410–416. DOI:<a href=\"https://doi.org/10.1177/1060028016685803\">10.1177/1060028016685803</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28056525/\">https://pubmed.ncbi.nlm.nih.gov/28056525</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Venetoclax;
